Meeting on the Med 2021 | The state of investment in cell & gene therapy

Matthew Durdy, Chief Executive, Cell and Gene Therapy Catapult, London, UK, describes the current state of investment in cell and gene therapy sector and outlines key takeaways from a recent panel discussion on this topic at the Cell & Gene Meeting on the Mediterranean 2021 conference. In the panel, it was highlighted that valuation approaches may have been impacted due to the COVID-19 pandemic due to the recognition of the importance of the healthcare industry within national infrastructures, as well as an increase in investment in manufacturing infrastructure. This interview took place during the Cell & Gene Meeting on the Mediterranean 2021 virtual conference.